Amgen Inc. (NASDAQ:AMGN)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $176.64 and last traded at $175.45, with a volume of 2,004,648 shares changing hands. The stock had previously closed at $174.31.

Several equities research analysts have recently issued reports on AMGN shares. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $168.64 target price on the stock in a report on Wednesday, April 27th. Morgan Stanley reaffirmed a “buy” rating and issued a $195.00 target price on shares of Amgen in a report on Friday, April 29th. Leerink Swann reaffirmed a “market perform” rating and issued a $186.00 target price (up from $179.00) on shares of Amgen in a report on Sunday, May 1st. BMO Capital Markets reaffirmed a “buy” rating and issued a $186.00 target price (up from $183.00) on shares of Amgen in a report on Saturday, April 30th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Amgen in a report on Saturday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $184.92.

The firm has a 50 day moving average price of $167.32 and a 200-day moving average price of $155.84. The company has a market capitalization of $129.93 billion and a P/E ratio of 17.77.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. During the same quarter in the previous year, the company posted $2.57 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post $11.37 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th will be issued a dividend of $1.00 per share. The ex-dividend date of this dividend is Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.30%.

In other news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Several hedge funds have recently made changes to their positions in the company. Freestone Capital Holdings LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $1,099,000. TCI Wealth Advisors Inc. increased its stake in shares of Amgen by 4.4% in the fourth quarter. TCI Wealth Advisors Inc. now owns 11,884 shares of the medical research company’s stock worth $1,929,000 after buying an additional 506 shares in the last quarter. Atlanta Capital Group purchased a new stake in shares of Amgen during the fourth quarter worth about $1,938,000. Girard Partners LTD. increased its stake in shares of Amgen by 61.8% in the fourth quarter. Girard Partners LTD. now owns 12,171 shares of the medical research company’s stock worth $1,976,000 after buying an additional 4,651 shares in the last quarter. Finally, TrimTabs Asset Management LLC increased its stake in shares of Amgen by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 14,887 shares of the medical research company’s stock worth $2,417,000 after buying an additional 274 shares in the last quarter.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.